| __timestamp | Verona Pharma plc | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1802274 | 5496000 |
| Thursday, January 1, 2015 | 2512761 | 9786000 |
| Friday, January 1, 2016 | 2894488 | 6792000 |
| Sunday, January 1, 2017 | 8096274 | 7313000 |
| Monday, January 1, 2018 | 7985229 | 8382000 |
| Tuesday, January 1, 2019 | 8994597 | 10803000 |
| Wednesday, January 1, 2020 | 29772000 | 12944000 |
| Friday, January 1, 2021 | 33907000 | 21967000 |
| Saturday, January 1, 2022 | 26579000 | 32810000 |
| Sunday, January 1, 2023 | 49868547 | 46542000 |
Infusing magic into the data realm
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Verona Pharma plc and Xenon Pharmaceuticals Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Verona Pharma's SG&A expenses surged by over 2,600%, peaking at nearly $50 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. Meanwhile, Xenon Pharmaceuticals saw a more modest increase of approximately 750%, reaching around $46 million in the same year. This suggests a more measured approach to scaling their operations. The data highlights the strategic choices each company has made in managing their operational costs, offering valuable insights into their business models and growth strategies. As the biopharma industry continues to evolve, understanding these financial dynamics is key for investors and stakeholders alike.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or MorphoSys AG
Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Perrigo Company plc vs Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. vs MorphoSys AG: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.